22169-Peritoneal Cancer-NA-150

Peritoneal Cancer

Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081)

  • Details

ClinicalTrials.gov ID: NCT05446298
Diagnosis Type: NA
USOR Number:

  • Address

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

Search by practice name, trial titles, indicators and specific disease types.